Last reviewed · How we verify

NCT03659500

Clinical Outcomes and Costs of 4-Week Versus 6-Week Bloodwork for Patients on Hemodialysis

Completed Last updated 3 April 2024
What this trial tests

trial testing Four-week routine bloodwork in End Stage Renal Disease in 400 participants. Completed in 31 December 2015.

Timeline
1 June 2012
Primary endpoint
31 December 2015
31 December 2015

Quick facts

Lead sponsorSamuel Silver
StatusCompleted
Study typeOBSERVATIONAL
Enrollment400
Start date1 June 2012
Primary completion31 December 2015
Estimated completion31 December 2015

Drugs / interventions tested

Conditions studied

Sponsor

Samuel Silver

Who can join

Eligibility, any sex, with End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this quality improvement study was to determine the effect of an institution-wide switch of routine bloodwork from four-week intervals to six-week intervals on the achievement of anemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) targets for patients on chronic hemodialysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for End Stage Renal Disease

Currently open trials in the same condition.

Other Samuel Silver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03659500.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing